Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction

Irene M. Ghobrial, Robert C. Wolf, Denise L Pereira, Rafael Fonseca, William L. White, Joseph P. Colgan, Thomas M. Habermann, David J. Inwards, Svetomir N. Markovic, Stephen M. Ansell, Ivana N M Micallef, Luis F. Porrata, Thomas E. Witzig

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Objectives: To determine the long-term outcome of patients presenting with synchronous lymphoma and severe liver dysfunction and to describe the outcome of patients treated with initial mechlorethamine-based therapy used as a bridge to more conventional chemotherapy. Patients and Methods: We reviewed the clinical course of all patients diagnosed as having lymphoma who presented with severe liver dysfunction and received intravenous mechlorethamine between September 1988 and February 2003 at the Mayo Clinic in Rochester, Minn. Results: Forty-one patients were identified, 33 (80%) of whom had newly diagnosed, previously untreated lymphoma. Thirty-seven (90%) had non-Hodgkin lymphoma, and 4 (10%) had Hodgkin disease. Thirty-four patients (83%) had stage IV disease, and 31 (84%) of 37 had an intermediate-high International Prognostic Index. The median total bilirubin level before therapy was 10.7 mg/dL (range, 2.5-30.2 mg/dL), and the median alkaline phosphatase level was 982 U/L (range, 233-3415 U/L). In addition to mechlorethamine, 34 patients (83%) received concomitant corticosteroids, and 12 (29%) received concomitant rituximab. Twenty-two patients (54%) had sufficient improvement in liver function to receive subsequent standard chemotherapy. Nine patients (22%) are alive and disease-free at a median of 31 months (range, 4 to ≥87 months) after mechlorethamine treatment. Factors associated with improved overall survival included improvement in bilirubin levels (P<.001) and receiving subsequent standard chemotherapy (P=.001). Conclusion: Mechlorethamine, high-dose corticosteroids, and rituximab are useful therapeutic interventions for this unique group of patients with lymphoma and severe liver dysfunction. Substantial clinical improvement and long-term survival are possible.

Original languageEnglish
Pages (from-to)169-175
Number of pages7
JournalMayo Clinic Proceedings
Volume79
Issue number2
StatePublished - Jan 1 2004
Externally publishedYes

Fingerprint

Liver Diseases
Lymphoma
Mechlorethamine
Therapeutics
Bilirubin
Drug Therapy
Adrenal Cortex Hormones
Survival
Hodgkin Disease
Non-Hodgkin's Lymphoma
Alkaline Phosphatase
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Ghobrial, I. M., Wolf, R. C., Pereira, D. L., Fonseca, R., White, W. L., Colgan, J. P., ... Witzig, T. E. (2004). Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction. Mayo Clinic Proceedings, 79(2), 169-175.

Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction. / Ghobrial, Irene M.; Wolf, Robert C.; Pereira, Denise L; Fonseca, Rafael; White, William L.; Colgan, Joseph P.; Habermann, Thomas M.; Inwards, David J.; Markovic, Svetomir N.; Ansell, Stephen M.; Micallef, Ivana N M; Porrata, Luis F.; Witzig, Thomas E.

In: Mayo Clinic Proceedings, Vol. 79, No. 2, 01.01.2004, p. 169-175.

Research output: Contribution to journalArticle

Ghobrial, IM, Wolf, RC, Pereira, DL, Fonseca, R, White, WL, Colgan, JP, Habermann, TM, Inwards, DJ, Markovic, SN, Ansell, SM, Micallef, INM, Porrata, LF & Witzig, TE 2004, 'Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction', Mayo Clinic Proceedings, vol. 79, no. 2, pp. 169-175.
Ghobrial IM, Wolf RC, Pereira DL, Fonseca R, White WL, Colgan JP et al. Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction. Mayo Clinic Proceedings. 2004 Jan 1;79(2):169-175.
Ghobrial, Irene M. ; Wolf, Robert C. ; Pereira, Denise L ; Fonseca, Rafael ; White, William L. ; Colgan, Joseph P. ; Habermann, Thomas M. ; Inwards, David J. ; Markovic, Svetomir N. ; Ansell, Stephen M. ; Micallef, Ivana N M ; Porrata, Luis F. ; Witzig, Thomas E. / Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction. In: Mayo Clinic Proceedings. 2004 ; Vol. 79, No. 2. pp. 169-175.
@article{c89325b7020744fc8645c2ab9c2ef9a4,
title = "Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction",
abstract = "Objectives: To determine the long-term outcome of patients presenting with synchronous lymphoma and severe liver dysfunction and to describe the outcome of patients treated with initial mechlorethamine-based therapy used as a bridge to more conventional chemotherapy. Patients and Methods: We reviewed the clinical course of all patients diagnosed as having lymphoma who presented with severe liver dysfunction and received intravenous mechlorethamine between September 1988 and February 2003 at the Mayo Clinic in Rochester, Minn. Results: Forty-one patients were identified, 33 (80{\%}) of whom had newly diagnosed, previously untreated lymphoma. Thirty-seven (90{\%}) had non-Hodgkin lymphoma, and 4 (10{\%}) had Hodgkin disease. Thirty-four patients (83{\%}) had stage IV disease, and 31 (84{\%}) of 37 had an intermediate-high International Prognostic Index. The median total bilirubin level before therapy was 10.7 mg/dL (range, 2.5-30.2 mg/dL), and the median alkaline phosphatase level was 982 U/L (range, 233-3415 U/L). In addition to mechlorethamine, 34 patients (83{\%}) received concomitant corticosteroids, and 12 (29{\%}) received concomitant rituximab. Twenty-two patients (54{\%}) had sufficient improvement in liver function to receive subsequent standard chemotherapy. Nine patients (22{\%}) are alive and disease-free at a median of 31 months (range, 4 to ≥87 months) after mechlorethamine treatment. Factors associated with improved overall survival included improvement in bilirubin levels (P<.001) and receiving subsequent standard chemotherapy (P=.001). Conclusion: Mechlorethamine, high-dose corticosteroids, and rituximab are useful therapeutic interventions for this unique group of patients with lymphoma and severe liver dysfunction. Substantial clinical improvement and long-term survival are possible.",
author = "Ghobrial, {Irene M.} and Wolf, {Robert C.} and Pereira, {Denise L} and Rafael Fonseca and White, {William L.} and Colgan, {Joseph P.} and Habermann, {Thomas M.} and Inwards, {David J.} and Markovic, {Svetomir N.} and Ansell, {Stephen M.} and Micallef, {Ivana N M} and Porrata, {Luis F.} and Witzig, {Thomas E.}",
year = "2004",
month = "1",
day = "1",
language = "English",
volume = "79",
pages = "169--175",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "2",

}

TY - JOUR

T1 - Therapeutic Options in Patients with Lymphoma and Severe Liver Dysfunction

AU - Ghobrial, Irene M.

AU - Wolf, Robert C.

AU - Pereira, Denise L

AU - Fonseca, Rafael

AU - White, William L.

AU - Colgan, Joseph P.

AU - Habermann, Thomas M.

AU - Inwards, David J.

AU - Markovic, Svetomir N.

AU - Ansell, Stephen M.

AU - Micallef, Ivana N M

AU - Porrata, Luis F.

AU - Witzig, Thomas E.

PY - 2004/1/1

Y1 - 2004/1/1

N2 - Objectives: To determine the long-term outcome of patients presenting with synchronous lymphoma and severe liver dysfunction and to describe the outcome of patients treated with initial mechlorethamine-based therapy used as a bridge to more conventional chemotherapy. Patients and Methods: We reviewed the clinical course of all patients diagnosed as having lymphoma who presented with severe liver dysfunction and received intravenous mechlorethamine between September 1988 and February 2003 at the Mayo Clinic in Rochester, Minn. Results: Forty-one patients were identified, 33 (80%) of whom had newly diagnosed, previously untreated lymphoma. Thirty-seven (90%) had non-Hodgkin lymphoma, and 4 (10%) had Hodgkin disease. Thirty-four patients (83%) had stage IV disease, and 31 (84%) of 37 had an intermediate-high International Prognostic Index. The median total bilirubin level before therapy was 10.7 mg/dL (range, 2.5-30.2 mg/dL), and the median alkaline phosphatase level was 982 U/L (range, 233-3415 U/L). In addition to mechlorethamine, 34 patients (83%) received concomitant corticosteroids, and 12 (29%) received concomitant rituximab. Twenty-two patients (54%) had sufficient improvement in liver function to receive subsequent standard chemotherapy. Nine patients (22%) are alive and disease-free at a median of 31 months (range, 4 to ≥87 months) after mechlorethamine treatment. Factors associated with improved overall survival included improvement in bilirubin levels (P<.001) and receiving subsequent standard chemotherapy (P=.001). Conclusion: Mechlorethamine, high-dose corticosteroids, and rituximab are useful therapeutic interventions for this unique group of patients with lymphoma and severe liver dysfunction. Substantial clinical improvement and long-term survival are possible.

AB - Objectives: To determine the long-term outcome of patients presenting with synchronous lymphoma and severe liver dysfunction and to describe the outcome of patients treated with initial mechlorethamine-based therapy used as a bridge to more conventional chemotherapy. Patients and Methods: We reviewed the clinical course of all patients diagnosed as having lymphoma who presented with severe liver dysfunction and received intravenous mechlorethamine between September 1988 and February 2003 at the Mayo Clinic in Rochester, Minn. Results: Forty-one patients were identified, 33 (80%) of whom had newly diagnosed, previously untreated lymphoma. Thirty-seven (90%) had non-Hodgkin lymphoma, and 4 (10%) had Hodgkin disease. Thirty-four patients (83%) had stage IV disease, and 31 (84%) of 37 had an intermediate-high International Prognostic Index. The median total bilirubin level before therapy was 10.7 mg/dL (range, 2.5-30.2 mg/dL), and the median alkaline phosphatase level was 982 U/L (range, 233-3415 U/L). In addition to mechlorethamine, 34 patients (83%) received concomitant corticosteroids, and 12 (29%) received concomitant rituximab. Twenty-two patients (54%) had sufficient improvement in liver function to receive subsequent standard chemotherapy. Nine patients (22%) are alive and disease-free at a median of 31 months (range, 4 to ≥87 months) after mechlorethamine treatment. Factors associated with improved overall survival included improvement in bilirubin levels (P<.001) and receiving subsequent standard chemotherapy (P=.001). Conclusion: Mechlorethamine, high-dose corticosteroids, and rituximab are useful therapeutic interventions for this unique group of patients with lymphoma and severe liver dysfunction. Substantial clinical improvement and long-term survival are possible.

UR - http://www.scopus.com/inward/record.url?scp=9144269623&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=9144269623&partnerID=8YFLogxK

M3 - Article

C2 - 14959910

AN - SCOPUS:9144269623

VL - 79

SP - 169

EP - 175

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 2

ER -